Netflix starts strong, Palantir receives upgrade: Leading analyst picks from Wall Street

Today's Key Wall Street Analyst Actions

Stay updated with the most significant analyst recommendations and market-moving research from across Wall Street. Below are the latest upgrades, downgrades, and new coverage highlights that investors should be aware of.

Top 5 Analyst Upgrades

• B. Riley on Airbnb (ABNB): Upgraded to Buy from Neutral, with the price target raised to $170 from $140. The firm points to Airbnb's appealing valuation and expects ongoing robust growth and improved margins.
• Citi on Palantir (PLTR): Upgraded to Buy from Neutral, increasing the price target to $235 from $210. Citi anticipates that consensus estimates for Palantir will rise significantly by 2026.
• BofA on Comcast (CMCSA): Upgraded to Buy from Neutral, with the price target moving up to $37 from $31. BofA expects major industry changes in 2026, including consolidation and new opportunities in content, technology, and live events.
• Citi on Zoom Communications (ZM): Upgraded to Buy from Neutral, with a new price target of $106, up from $94. Citi considers the stock attractively valued, given Zoom's path to steady 5% sales growth.
• Morgan Stanley on Datadog (DDOG): Upgraded to Overweight from Equal Weight, maintaining a $180 price target. The firm notes that Datadog's growth trajectory is strengthening as 2026 approaches.

Top 5 Analyst Downgrades

• Wolfe Research on Rivian (RIVN): Downgraded to Underperform from Peer Perform with a $16 price target. Wolfe Research sees an unfavorable risk/reward profile, citing weakened fundamentals despite recent share gains and overly optimistic 2026 expectations.
• Barclays on Snowflake (SNOW): Downgraded to Equal Weight from Overweight, lowering the price target to $250 from $290. The downgrade follows a 42% rally in the stock during 2025, with valuation concerns cited.
• Barclays on Insulet (PODD): Downgraded to Underweight from Equal Weight, with the price target reduced to $274 from $316. Barclays points to increasing competition in the automated insulin delivery market, which could pressure Insulet's valuation.
• TD Cowen on Allstate (ALL): Downgraded to Hold from Buy, with the price target raised to $231 from $224. The firm notes heightened competition in the personal auto insurance sector.
• KeyBanc on CrowdStrike (CRWD): Downgraded to Sector Weight from Overweight, with no price target provided. KeyBanc's 2026 outlook highlights more balanced security spending intentions, as indicated by recent surveys.

Top 5 New Analyst Coverages

• HSBC on Netflix (NFLX): Initiated with a Buy rating and a $107 price target. HSBC notes Netflix's acquisition strategy as a response to a maturing streaming market and recognizes the company as the clear global leader in streaming.
• Barclays on Medline (MDLN): Initiated with an Overweight rating and a $50 price target. Barclays highlights Medline's scale, private-label strengths, and logistics. Multiple other firms, including Wolfe Research, Leerink, JPMorgan, and others, also began coverage with Buy-equivalent ratings, while Deutsche Bank, Wells Fargo, Rothschild & Co Redburn, and BNP Paribas started with Neutral-equivalent ratings.
• Baird on Andersen Group (ANDG): Initiated with an Outperform rating and a $40 price target. Baird describes Andersen as a top-tier provider of tax, valuation, and advisory services for high-net-worth clients and institutions. UBS, William Blair, Deutsche Bank, and Truist also initiated with Buy-equivalent ratings, while Morgan Stanley and Wells Fargo started with Neutral-equivalent ratings.
• JPMorgan on Rocket Companies (RKT): Resumed coverage with a Neutral rating and a $24 price target after a restriction period. JPMorgan is positive on Rocket's new strategy but believes the market has already priced in potential benefits from lower rates and market share gains.
• Evercore ISI on Hims & Hers (HIMS): Initiated with an In Line rating and a $33 price target. Evercore ISI sees the current valuation as fair, though it feels the market may be underestimating the strength and diversity of Hims' core business.